NeuroBo Pharmaceuticals, Inc. (NRBO)
After hours:
| Previous Close | 2.3800 |
| Open | 2.3800 |
| Bid | 1.7500 x 200 |
| Ask | 3.0200 x 200 |
| Day's Range | 2.3500 - 2.4500 |
| 52 Week Range | 2.0800 - 6.7500 |
| Volume | |
| Avg. Volume | 44,825 |
| Market Cap | 20.42M |
| Beta (5Y Monthly) | -0.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.2900 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.67 |
PR NewswireNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic Diseases
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date"). In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the
GlobeNewswireLife Sciences Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held November 14th are now available for online viewing. REGISTER NOW AT: https://bit.ly/4fMrinK The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download inve
